Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineBlackRock Throgmorton shoots the lights out amid mid-cap momentum
BlackRock Throgmorton (THRG) 916.59p
Gain to date: 30.4%
Original entry point: Buy at 702.79p, 26 November 2020
Our call to buy investment trust BlackRock Throgmorton (THRG) for its focus on quality companies which had been sold off in the initial value rally has proved a canny trade.
The portfolio is dominated by small and mid-cap names which have performed strongly in the interim. A portfolio update on 11 May revealed that in the three months to 30 April the net asset value and share price had increased 18.4% against a 15.6% advance in the benchmark.
A big contributor to this positive showing has been ESG-focused asset manager Impax Asset Management (IPX:AIM) as well as building materials firm Grafton (GFTU) and pharmaceutical services company Ergomed (ERGO:AIM), which announced an expansion in Japan in April.
Commenting on the recent performance fund manager Dan Whitestone said: ‘The general pattern was of strong trading with good growth even for those who grew very fast in 2020, and so the higher share prices now are justified by the higher profits than had been expected a year ago.’
SHARES SAYS: The trust’s focus on quality small and mid caps should stand it in good stead for the longer term. Still a buy.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Case study
Great Ideas
- SkinBio Therapeutics' psoriasis supplement could be a real money spinner
- BlackRock Throgmorton shoots the lights out amid mid-cap momentum
- Change at the top to supercharge Brown Advisory US Smaller Companies
- Why Lindsell Train loves Diageo as much as we do
- Aurora Investment Trust moves into top gear thanks to value tailwind
- Inditex's sales and earnings growth defy the doubters
Investment Trusts
Money Matters
News
- Record job additions not sparking inflation fears yet
- Markets unmoved by lockdown easing delay
- Space the new frontier for investors as ETF and investment trust launch
- GlaxoSmithKline to spin-off £30 billion consumer healthcare arm in 2022
- Regulator tells companies to prioritise pensions over dividends
